Close menu
Open menu
Identification of Novel Cancer-Specific Splice Variants Using Oxford BioTherapeutics' Ultra-High Sensitivity Tissue Membrane Proteomics Database, OGAP®-Verify, for First-in-class ADCs and Other Therapeutic Antibodies
Addressing Unmet Clinical Oncology Needs Through a Novel Therapeutic ADC Target Space in Cancer Patient Tissue Biopsies Using
OGAP®-Verify
Novel Target Identification Using Oxford BioTherapeutics' Proprietary Proteomics Target Discovery, OGAP(R), for First-in-Class ADCs and Other Antibody Therapeutics
Oxford BioTherapeutics and ImmunoGen Partner to Develop Multiple First-in Class Antibody-Drug Conjugates in Cancer Indications with High Unmet Clinical Need
A Novel B7-H6-targeted IgG-like T-cell Engaging Antibody for the Treatment of Gastrointestinal Tumors.
Analysis of tumor infiltrating lymphocytes and in vitro exhausted T cell models to identify unique Immuno-Oncology targets
The use of proteomics to analyse whole tumors and identify unique stroma cell targets for antibody-based therapeutics
The use of proteomics to analyze whole tumors and identify unique immuno-oncology targets for antibody-based therapeutics
Proteomics and Selecting the Right Combination of Target and Toxin for Antibody-Drug-Conjugate (ADC) Development
Proteomics highlights which G-protein coupled receptors are candidates for ADC development